Top Markets
Coin of the day
Harpoon Therapeutics, Inc. Harpoon Therapeutics, Inc.

Harpoon Therapeutics, Inc.

HARP
주식 순위 #23352
Harpoon Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to... Harpoon Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to immunotherapy, focused on engineering a novel class of T cell activators. These therapies are designed to leverage the body's own immune system to fight cancer and other diseases in patients across the United States. The company's innovative Tri-specific T cell activating construct (TriTAC) platform forms the basis of its development pipeline. This includes HPN328, currently undergoing Phase I/II clinical trials for small cell lung cancer and tumors that express Delta-like canonical Notch ligand 3; HPN217, also in Phase I/II trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical evaluation for ovarian and pancreatic cancers, alongside other mesothelin-expressing tumors. Furthermore, Harpoon has a preclinical asset, HPN601, aimed at various solid tumor indications. The company has also established a discovery collaboration and licensing agreement with AbbVie Biotechnology Ltd. to develop and market products combining its unique TriTAC technology with soluble T cell receptors. Founded in 2015, Harpoon Therapeutics, Inc. is headquartered in South San Francisco, California.
주가
$23.01
마지막 동기화: 2024-03-11
시가총액
$74.80M
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Harpoon Therapeutics, Inc. (HARP)

카테고리

Harpoon Therapeutics, Inc. (HARP)의 배당 수익률 기록
Harpoon Therapeutics, Inc. (주식 심볼: HARP)의 배당 수익률 (TTM)은 2026 기준으로 0입니다.
지난 5년 평균 배당 수익률: 0.00%
Harpoon Therapeutics, Inc. (HARP)의 배당 수익률 기록: 2026 ~ 2026
연도별 말 기준 배당 수익률 (TTM)
연도 배당 수익률 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 배당 수익률 (TTM)
회사 배당 수익률 국가
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH